Acute Dermato-Lymphangio-Adenitis Following Administration of Infliximab for Crohn's Disease.
Journal: 2019/October - ACG Case Reports Journal
ISSN: 2326-3253
Abstract:
Tumor necrosis factor-α inhibitor (TNF-α) is frequently used for Crohn's disease and other autoimmune conditions. Increased risk of infection is an accepted adverse effect of TNF-α, and routine screening for potential infections are carried out before initiation of therapy. We report the case of a patient who developed a localized painful swelling near the injection site, which was diagnosed as acute dermato-lymphangio-adenitis due to filarial infection. This adds to the limited number of case reports on parasitic complications following TNF-α therapy.
Relations:
Content
References
(12)
Diseases
(1)
Conditions
(2)
Drugs
(2)
Genes
(1)
Affiliates
(1)
Similar articles
Articles by the same authors
Discussion board
ACG Case Rep J 6(6): e00075

Acute Dermato-Lymphangio-Adenitis Following Administration of Infliximab for Crohn's Disease

Department of Pharmacology, Faculty of Medical Sciences, University of Sri Jayewardenepura, Nugegoda, Sri Lanka
Department of Clinical Medicine, Faculty of Medicine, Univeristy of Kelaniya, Ragama, Sri Lanka
Department of Parasitology, Faculty of Medicine, Univeristy of Kelaniya, Ragama, Sri Lanka
Corresponding author.
Correspondence: I.K. Liyanage, MBBS, MD, MRCP, Department of Pharmacology, Faculty of Medical Sciences, University of Sri Jayewardenepura, Nugegoda, Sri Lanka 10250 (moc.liamg@htijurusi).
Received 2018 Oct 15; Accepted 2019 Feb 1.
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

ABSTRACT

Tumor necrosis factor-α inhibitor (TNF-α) is frequently used for Crohn's disease and other autoimmune conditions. Increased risk of infection is an accepted adverse effect of TNF-α, and routine screening for potential infections are carried out before initiation of therapy. We report the case of a patient who developed a localized painful swelling near the injection site, which was diagnosed as acute dermato-lymphangio-adenitis due to filarial infection. This adds to the limited number of case reports on parasitic complications following TNF-α therapy.

ABSTRACT

REFERENCES

REFERENCES

References

  • 1. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105(3):501. [[PubMed]
  • 2. Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn's disease in adults. Am J Gastroenterol. 2018;113(4):481–517. [[PubMed]
  • 3. Sousa P, Allez M. Complications of biologics in inflammatory bowel disease. Curr Opin Gastroenterol. 2015;31(4):296–302. [[PubMed]
  • 4. Côté-Daigneault J, Bouin M, Lahaie R, Colombel J-F, Poitras P. Biologics in inflammatory bowel disease: What are the data?United Eur Gastroenterol J. 2015;3(5):419–28.
  • 5. Lichtenstein GR, Feagan BG, Cohen RD, et al Infliximab for Crohn's disease: More than 13 years of real-world experience. Inflamm Bowel Dis. 2018;24(3):490–501. [Google Scholar]
  • 6. Shenoy R. Clinical and pathological aspects of filarial lymphedema and its management. Korean J Parasitol. 2008;46(3):119.
  • 7. Behera M, Das S, Panda JK. Current Management: Filariasis. Medicine Update, 2017. Association of Physicians of India: Mumbai, India; 2017. [PubMed]
  • 8. Addiss DG, Brady MA. Morbidity management in the global programme to eliminate lymphatic filariasis: A review of the scientific literature. Filaria J. 2007;6(1):2.
  • 9. Rao RU, Nagodavithana KC, Samarasekera SD, et al A comprehensive assessment of lymphatic filariasis in Sri Lanka six years after cessation of mass drug administration. PLoS Negl Trop Dis. 2014;8(11):e3281. [Google Scholar]
  • 10. Weerasooriya MV. Elimination of Lymphatic Filariasis in Sri Lanka: Advances in Diagnosis and Management of Surveillance. Proceedings of the International Research Conference, General Sir John Kotelawala Defence University, Ratmalana, Sri Lanka: 2017. [PubMed]
  • 11. Lee HH, Song IH, Friedrich M, et al Cutaneous side‐effects in patients with rheumatic diseases during application of tumour necrosis factor‐α antagonists. Br J Dermatol. 2007;156(3):486–91. [[PubMed][Google Scholar]
  • 12. Cocca S, Guarino M, Cicala M. Asymptomatic parasitic infection in a Crohn's disease patient on anti-TNFα therapy: An alert for our patients?J Crohn's Colitis. 2016;10(12):1455–6. [[PubMed]
  • 13. Garner O, Ramirez-Berlioz A, Iardino A, Mocherla S, Bhairavarasu K. Disseminated nocardiosis associated with treatment with infliximab in a patient with ulcerative colitis. Am J Case Rep. 2017;18:1365–9.
  • 14. Koloski NA, Bret L, Radford-Smith G. Hygiene hypothesis in inflammatory bowel disease: A critical review of the literature. World J Gastroenterol. 2008;14(2):165.
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.